Sameh Tawfik

Array ( [id] => 18910515 [patent_doc_number] => 11873486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon [patent_app_type] => utility [patent_app_number] => 16/497294 [patent_app_country] => US [patent_app_date] => 2018-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 91 [patent_figures_cnt] => 68 [patent_no_of_words] => 109502 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16497294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253806 [patent_doc_number] => 20200263180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES [patent_app_type] => utility [patent_app_number] => 16/490494 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16490494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13790719 [patent_doc_number] => 20190008898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => Inhibition of Diacylglycerol Kinase to Augment Adoptive T cell Transfer [patent_app_type] => utility [patent_app_number] => 15/908388 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15908388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17953679 [patent_doc_number] => 11479773 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-25 [patent_title] => Antisense nucleic acid for inhibiting biosynthesis of chondroitin sulfate [patent_app_type] => utility [patent_app_number] => 16/498102 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 19185 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13537281 [patent_doc_number] => 20180320187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => TOXIC RNAi ACTIVE SEED SEQUENCES FOR KILLING CANCER CELLS [patent_app_type] => utility [patent_app_number] => 15/900392 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58519 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15900392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17436126 [patent_doc_number] => 11261440 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-01 [patent_title] => Antisense oligonucleic acid [patent_app_type] => utility [patent_app_number] => 16/487762 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 13017 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18133939 [patent_doc_number] => 11559588 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders [patent_app_type] => utility [patent_app_number] => 16/487689 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 70846 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711591 [patent_doc_number] => 20200102561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES [patent_app_type] => utility [patent_app_number] => 16/484046 [patent_app_country] => US [patent_app_date] => 2018-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 109923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15396243 [patent_doc_number] => 10538768 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-21 [patent_title] => Modified TGF-beta oligonucleotides [patent_app_type] => utility [patent_app_number] => 15/882221 [patent_app_country] => US [patent_app_date] => 2018-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 67 [patent_no_of_words] => 15884 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15882221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14261739 [patent_doc_number] => 10280422 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-07 [patent_title] => MiR-92 inhibitors and uses thereof [patent_app_type] => utility [patent_app_number] => 15/878176 [patent_app_country] => US [patent_app_date] => 2018-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 24 [patent_no_of_words] => 20351 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15878176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12770671 [patent_doc_number] => 20180148725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => UNA OLIGOMERS AND COMPOSITIONS FOR TREATING AMYLOIDOSIS [patent_app_type] => utility [patent_app_number] => 15/876127 [patent_app_country] => US [patent_app_date] => 2018-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15876127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522595 [patent_doc_number] => 20180312840 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => COMPOUNDS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION FOR IMPROVING A DIABETIC PROFILE [patent_app_type] => utility [patent_app_number] => 15/874662 [patent_app_country] => US [patent_app_date] => 2018-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27052 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15874662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12770674 [patent_doc_number] => 20180148726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => RNAi Inhibition of Alpha-ENaC Expression [patent_app_type] => utility [patent_app_number] => 15/874396 [patent_app_country] => US [patent_app_date] => 2018-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35187 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15874396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12754102 [patent_doc_number] => 20180143201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => METHOD OF DETERMINING A PROTEIN IN A SAMPLE [patent_app_type] => utility [patent_app_number] => 15/871313 [patent_app_country] => US [patent_app_date] => 2018-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7514 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15871313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12909682 [patent_doc_number] => 20180195069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use [patent_app_type] => utility [patent_app_number] => 15/867107 [patent_app_country] => US [patent_app_date] => 2018-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15867107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12729652 [patent_doc_number] => 20180135051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => THERAPEUTIC OLIGOMERS FOR TREATING AMYLOIDOSIS [patent_app_type] => utility [patent_app_number] => 15/859571 [patent_app_country] => US [patent_app_date] => 2017-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15859571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13369127 [patent_doc_number] => 20180236104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => EXOSOME TRANSFER OF NUCLEIC ACIDS TO CELLS [patent_app_type] => utility [patent_app_number] => 15/857539 [patent_app_country] => US [patent_app_date] => 2017-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15857539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12661144 [patent_doc_number] => 20180112214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => Treatment Of Genetic Disorders Associated With DNA Repeat Instability [patent_app_type] => utility [patent_app_number] => 15/855848 [patent_app_country] => US [patent_app_date] => 2017-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15855848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12863098 [patent_doc_number] => 20180179540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => FUNCTIONAL LIGANDS TO OPIOIDS AND OPIOID METABOLITES [patent_app_type] => utility [patent_app_number] => 15/852941 [patent_app_country] => US [patent_app_date] => 2017-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15852941 [rel_patent_id] =>[rel_patent_doc_number] =>)